FOLD Key Statistics, Chart & Performance
The current stock price of FOLD is 14.28 USD. In the past month the price increased by 44.97%. In the past year, price increased by 58.31%.
FOLD Latest News, Press Relases and Analysis
FOLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About FOLD
Company Profile
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 499 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Company Info
AMICUS THERAPEUTICS INC
47 Hulfish Street
Princeton NEW JERSEY 19104 US
CEO: John F. Crowley
Employees: 499
Phone: 16096622000
AMICUS THERAPEUTICS INC / FOLD FAQ
What does FOLD do?
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 499 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
What is the current price of FOLD stock?
The current stock price of FOLD is 14.28 USD.
What is the dividend status of AMICUS THERAPEUTICS INC?
FOLD does not pay a dividend.
What is the ChartMill technical and fundamental rating of FOLD stock?
FOLD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the market capitalization of FOLD stock?
AMICUS THERAPEUTICS INC (FOLD) has a market capitalization of 4.41B USD. This makes FOLD a Mid Cap stock.
Can you provide the upcoming earnings date for AMICUS THERAPEUTICS INC?
AMICUS THERAPEUTICS INC (FOLD) will report earnings on 2026-02-17, after the market close.
Who owns AMICUS THERAPEUTICS INC?
You can find the ownership structure of AMICUS THERAPEUTICS INC (FOLD) on the Ownership tab.
FOLD Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FOLD. When comparing the yearly performance of all stocks, FOLD is one of the better performing stocks in the market, outperforming 94.5% of all stocks.
FOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FOLD. Both the profitability and the financial health of FOLD get a neutral evaluation. Nothing too spectacular is happening here.
FOLD Financial Highlights
Over the last trailing twelve months FOLD reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 91.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| Debt/Equity | 1.7 |
FOLD Forecast & Estimates
14 analysts have analysed FOLD and the average price target is 16.26 USD. This implies a price increase of 13.84% is expected in the next year compared to the current price of 14.28.
For the next year, analysts expect an EPS growth of 89.48% and a revenue growth 19.4% for FOLD